Liposomal mitoxantrone

Phase 2Small molecule

IInstitute of Hematology & Blood Diseases Hospital, China

Liposomal mitoxantrone is one of 63 small molecule programs targeting AML. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AMLRecruiting

LymphomaRecruiting

AMLPreclinical

Recruiting

LymphomaPhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

Cabenuva

GSK

Preclinical

1 4

Liposomal mitoxantrone

IInstitute of Hematology & Blood Diseases Hospital, China

Phase 2

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Lymphoma

NCT05958719

Q1 2029

PreclinicalRecruiting

AML

NCT07490288

Clinical

Trials by Indication[1]

Lymphoma1 trial

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05958719·37 enrolled

Refractory1 trial

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05823701·23 enrolled

AML1 trial

A Single-Arm, Open-Label Study of Venetoclax, Azacitidine, and Liposomal Mitoxantrone (VAM) as Induction Therapy in Newly-diagnosed Adult Patients With Acute Myeloid Leukemia (AML)

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07490288·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Liposomal mitoxantrone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liposomal mitoxantrone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liposomal mitoxantrone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Hematology & Blood Diseases Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInstitute of Hematology & Blood Diseases Hospital, China

Liposomal mitoxantrone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2029

Trials by Indication[1]

Lymphoma1 trial

Refractory1 trial

AML1 trial

References

Drug Info

Quick Facts

Related News